Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.3 USD | -0.90% | -.--% | -.--% |
06-04 | Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients | MT |
06-04 | Bristol Myers: positive results in liver cancer | CF |
Sales 2024 * | 46.09B 63.03B | Sales 2025 * | 46.06B 62.98B | Capitalization | 84.67B 116B |
---|---|---|---|---|---|
Net income 2024 * | -5.41B -7.4B | Net income 2025 * | 10.22B 13.98B | EV / Sales 2024 * | 2.68 x |
Net Debt 2024 * | 39.03B 53.38B | Net Debt 2025 * | 31.68B 43.32B | EV / Sales 2025 * | 2.53 x |
P/E ratio 2024 * |
-15.9
x | P/E ratio 2025 * |
7.9
x | Employees | - |
Yield 2024 * |
5.76% | Yield 2025 * |
6.05% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- BMY Stock
- BMY Stock